Data on novel DNA methylation changes induced by valproic acid in human hepatocytes

Area of Science:

• Hepatology
• Epigenetics
• Pharmacology

Background:

• Valproic acid (VPA) is a common antiepileptic drug with known liver toxicity, including steatosis.
• The precise mechanisms underlying VPA-induced steatosis remain unclear.
• Understanding these mechanisms is crucial for patient safety and drug development.

Purpose of the Study:

• To investigate the molecular mechanisms of VPA-induced liver steatosis.
• To identify changes in DNA methylation patterns associated with VPA treatment.
• To explore the role of epigenetics in drug-induced liver injury.

Main Methods:

• Primary human hepatocytes (PHHs) were exposed to VPA for 5 days.
• A 3-day washout period was implemented for a subset of treated cells.
• Differentially methylated DNA regions (DMRs) were identified using Methylated DNA Immuno-Precipitation sequencing (MeDIP-seq).

Main Results:

• VPA treatment induced significant changes in DNA methylation patterns in PHHs.
• Identified DMRs were associated with pathways implicated in VPA-induced steatosis.
• Persistent DMRs were observed even after VPA treatment cessation, highlighting long-term epigenetic alterations.
• The EP300 gene network was identified as a key player in persistent VPA effects.

Conclusions:

• DNA methylation patterns are altered by VPA, contributing to liver steatosis.
• Epigenetic modifications play a role in the development and persistence of drug-induced steatosis.
• These findings provide insights into the mechanisms of VPA hepatotoxicity and identify potential therapeutic targets.